41
Participants
Start Date
June 1, 2011
Primary Completion Date
June 1, 2015
Study Completion Date
July 1, 2015
Epoprostenol
Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
Lead Sponsor
Collaborators (1)
Chiltern International Ltd.
INDUSTRY
Effi-Stat
OTHER
Actelion
INDUSTRY